MACK vs. RIGL, VNDA, RGLS, XOMA, VSTM, EBS, LXRX, GLSI, OGI, and DSGN
Should you be buying Merrimack Pharmaceuticals stock or one of its competitors? The main competitors of Merrimack Pharmaceuticals include Rigel Pharmaceuticals (RIGL), Vanda Pharmaceuticals (VNDA), Regulus Therapeutics (RGLS), XOMA (XOMA), Verastem (VSTM), Emergent BioSolutions (EBS), Lexicon Pharmaceuticals (LXRX), Greenwich LifeSciences (GLSI), Organigram (OGI), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical preparations" industry.
Merrimack Pharmaceuticals (NASDAQ:MACK) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.
Merrimack Pharmaceuticals has higher earnings, but lower revenue than Rigel Pharmaceuticals. Merrimack Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Merrimack Pharmaceuticals and Merrimack Pharmaceuticals both had 1 articles in the media. Rigel Pharmaceuticals' average media sentiment score of 1.05 beat Merrimack Pharmaceuticals' score of -0.36 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.
Merrimack Pharmaceuticals has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.
Merrimack Pharmaceuticals has a net margin of 0.00% compared to Rigel Pharmaceuticals' net margin of -21.47%. Rigel Pharmaceuticals' return on equity of 0.00% beat Merrimack Pharmaceuticals' return on equity.
64.0% of Merrimack Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 28.9% of Merrimack Pharmaceuticals shares are owned by company insiders. Comparatively, 8.4% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Rigel Pharmaceuticals received 50 more outperform votes than Merrimack Pharmaceuticals when rated by MarketBeat users. Likewise, 68.81% of users gave Rigel Pharmaceuticals an outperform vote while only 67.00% of users gave Merrimack Pharmaceuticals an outperform vote.
Rigel Pharmaceuticals has a consensus target price of $5.81, indicating a potential upside of 453.57%. Given Rigel Pharmaceuticals' higher probable upside, analysts clearly believe Rigel Pharmaceuticals is more favorable than Merrimack Pharmaceuticals.
Summary
Rigel Pharmaceuticals beats Merrimack Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Merrimack Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MACK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Merrimack Pharmaceuticals Competitors List
Related Companies and Tools
